MoHealthNet

Smart PA

Drug Monograph

Drug/Drug Class:	**Vabomere® (meropenem/vaborbactam) powder/solution for injection /Antibiotics**
Prepared for:	MO HealthNet
Prepared by:	Conduent

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Vabomere® is available as a sterile powder for constitution in single dose vials containing meropenem 1 gram and vaborbactam 1 gram.
Manufacturer:	Marketed by: The Medicines Company, Parsippany, NJ 07054
Indications:	Vabomere® is indicated for the treatment of patients 18 years of age and older with complicated urinary tract infections including pyelonephritis caused by the following susceptible microorganisms: *Escherichia coli, Kiebsiella pneumonia*, and *Enterobacter cloacae species* complex
Costs:	$165 per vial of Vabomere®. Wholesale Acquisition Cost
Summary of Findings:	MO HealthNet Division recommends Open Access status for this product.
Status Recommendation:	☐ Prior Authorization (PA) Required ☒ Open Access ☐ Fiscal Edit ☐ PDL
Type of PA Criteria:	☐ Increased Risk of ADE ☐ Under Solicitation ☐ Appropriate Indications ☒ No PA Required

Prepared By: Luke Boehmer PharmD
Date: February 19, 2018

© 2018 Conduent Business Services, LLC All Rights Reserved.